DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
DICE Therapeutics, Inc. is a biotechnology research company focused on developing oral medicines for chronic autoimmune and inflammatory diseases, grounded in validated immunology targets. By combining innovative chemistry with well-validated biology, it aims to make treatments more accessible and unlock the potential of oral therapies. The organization operates as a wholly owned subsidiary of Eli Lilly and Company and is based in South San Francisco, California, with a mid-sized team. Its leadership comprises scientists and senior executives with track records of advancing programs from discovery through regulatory milestones toward commercialization. The firm is building a pipeline of novel oral candidates across immunology and related therapeutic areas, supported by a platform that underpins small molecule discovery and development.